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Abstract
The neuropeptide substance P (SP) has been implicated in the disruption of the blood-brain barrier (BBB) and development
of cerebral edema in acute brain injury. Cerebral edema accumulates rapidly around brain tumors and has been linked to
several tumor-associated deficits. Currently, the standard treatment for peritumoral edema is the corticosteroid
dexamethasone, prolonged use of which is associated with a number of deleterious side effects. As SP is reported to
increase in many cancer types, this study examined whether SP plays a role in the genesis of brain peritumoral edema. A-
375 human melanoma cells were injected into the right striatum of male Balb/c nude mice to induce brain tumor growth,
with culture medium injected in animals serving as controls. At 2, 3 or 4 weeks following tumor cell inoculation, non-treated
animals were perfusion fixed for immunohistochemical detection of Albumin, SP and NK1 receptor. A further subgroup of
animals was treated with a daily injection of the NK1 antagonist Emend (3 mg/kg), dexamethasone (8 mg/kg) or saline
vehicle at 3 weeks post-inoculation. Animals were sacrificed a week later to determine BBB permeability using Evan’s Blue
and brain water content. Non-treated animals demonstrated a significant increase in albumin, SP and NK1 receptor
immunoreactivity in the peritumoral area as well as increased perivascular staining in the surrounding brain tissue. Brain
water content and BBB permeability was significantly increased in tumor-inoculated animals when compared to controls
(p,0.05). Treatment with Emend and dexamethasone reduced BBB permeability and brain water content when compared
to vehicle-treated tumor-inoculated mice. The increase in peritumoral staining for both SP and the NK1 receptor, coupled
with the reduction in brain water content and BBB permeability seen following treatment with the NK1 antagonist Emend,
suggests that SP plays a role in the genesis of peritumoral edema, and thus warrants further investigation as a potential
anti-edematous treatment.
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Introduction
Brain tumors are one of the most devastating forms of cancer,
and unlike many other cancer types, their incidence is increasing.
Currently within Australia, 1400 new cases of malignant brain
tumors are diagnosed and approximately 1100 people die from the
disease each year [1]. Astrocytomas and metastatic carcinomas are
the most common types of brain tumors in adults. Metastatic brain
tumors are up to 10 times more common than primary tumors of
the brain [2] and frequently originate from primary carcinomas of
breast, lung and colon, as well as melanomas [3]. Despite recent
advances in cancer treatment, brain tumors remain inherently
difficult to treat and prognosis for these patients remains extremely
poor, with most individuals succumbing to the disease within
months of diagnosis.
Both aggressive astrocytomas and secondary brain tumors are
associated with significant edema formation, which results in
substantial morbidity and mortality amongst patients. Indeed,
edematous fluid can accumulate rapidly around the tumors at
volumes of up to 90 ml per day [4,5]. Due to the rigid nature of
the skull, accumulation of this fluid is associated with a number of
deleterious consequences and if left untreated can result in
ischemia, herniation and death [6]. Brain tumor-associated edema
is typically vasogenic in nature, arising from the flux of fluids
across a compromised blood-brain barrier (BBB). Under normal
physiological circumstances, the BBB is made up of endothelial
cells joined by tight junctions. Tight junctions consist of molecules
such as claudin-3, claudin-5 and claudin-12, as well as other
transmembrane proteins such as occludin [7]. The disruption to
the BBB surrounding tumors is thought to result from defects in
these tight junctions, with abnormal expression of tight junction
molecules reported to correlate with increasing malignancy [8].
Despite extensive knowledge of the structure of the BBB,
molecular mechanisms for the disruption associated with brain
tumor growth remains poorly understood.
Recent research has implicated substance P (SP) in the genesis
of edema formation following other types of injury to the CNS [9-
12]. SP is a neuropeptide that is released from perivascular sensory
nerve fibres and preferentially binds to the NK1 receptor.
Mechanical stimulation of these fibres following injury causes SP
release and the subsequent development of neurogenic inflamma-
tion. Neurogenic inflammation is characterised by increased
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vasodilation, plasma extravasation and thus, edema formation
[11]. Research has shown that there is a significant increase in SP
immunoreactivity in perivascular tissue and within brain neuropil
5 hours post trauma, which corresponded with significant
increases in cerebral edema [10]. Subsequent administration of
an NK1 antagonist was found to attenuate this edema formation
and thereby improved neurological outcome [10]. Similarly
Turner et al (2006) showed that SP immunoreactivity was
increased in the infarcted hemisphere post stroke and was
associated with profound edema formation. As was observed in
TBI, administration of a SP antagonist resulted in marked
improvement in functional outcome following stroke [12]. Given
its role in the development of edema following these insults to the
CNS, and that SP expression is increased in a variety of human
cancer cell lines including brain tumors [13–16], SP may also be a
potential target for the treatment of metastatic brain tumor-
associated edema [9–12].
However, it is not yet known whether SP levels are increased
within the peri-tumoral region and if it plays a role in the genesis of
tumor-associated edema. Thus, the aims of the current study were
to examine the role of SP in tumor-associated edema in a model of
brain tumors secondary to melanoma, and to establish whether




A-375 human melanoma cells were obtained from American
Type Culture Collection (ATCC, CRL-1619). For all experiments,
A-375 cells were placed in 150 cm2 flasks with 20 mL of complete
culture medium (CCM) consisting of Dulbecco’s modified Eagle’s
medium (DMEM), 10% fetal bovine serum (FBS), 5% L-glutamine
and 1% penicillin and streptomycin. For tumor cell inoculation, A-
375 cells were passaged once to .90% confluence before the
CCM was removed from the flask and 3.5 mL of trypsin added to
detach cells. Subsequently, 7.5 mL of CCM was added and the
cells centrifuged for 5 minutes at 1500 RPM. Cells were re-
suspended in serum free media and counted using a haemocy-
tometer and then diluted, so that ,105 cells/5 mL were available
for tumor cell inoculation.
Animals
Animal procedures were performed in accordance with the
National Health and Medical Research Council guidelines and
were approved by the University of Adelaide and Institute of
Medical and Veterinary Science animal ethics committees. All
experimental work was performed using male Balb/C nude mice
(n = 70) aged 8–10 weeks, weighing between 17 and 22 g. Animals
were randomly assigned to each experimental group and were
housed in specific pathogen free conditions at 24uC on a 12-hour
day-night cycle. Animals were allowed access to standard rodent
pellets and water ad libitum.
Implantation of Tumor Cells
Tumor cell inoculation was performed using stereotaxic
implantation of,105/5 mL A-375 human melanoma cells. Briefly,
mice were anaesthetised with 3% Isoflurane and placed in a
stereotaxic frame, with anaesthesia maintained at 1.5% Isoflurane
using a nose cone. Tumour cells were injected into the right
striatum, 0-mm anterior and 2.5-mm lateral to the bregma and 3-
mm deep over 10 minutes. Following injection, the needle
remained in the brain for an additional 5 minutes to allow tumor
cells to disperse.
Treatment
At 3 weeks following tumor cell inoculation, animals were
randomly assigned to receive treatment of saline vehicle control,
the NK1 antagonist fosaprepitant diglutemide commonly known
as Emend (Merck & Co) (3 mg/kg/day) or the positive control,
dexamethasone (DBL) (8 mg/kg), which is the current clinical
treatment for brain tumor-associated edema. Animals received a
daily intraperitoneal injection of their assigned treatment for 7
days prior to euthanasia (n = 6 per Evan’s Blue group, n= 5 per
brain water content group). Emend was prepared by dissolving the
drug in saline, with the vehicle control animals administered saline
only. The dose of Emend was determined from previous studies,
which have demonstrated this administration exerts central effects
[17]. The dexamethasone dosage has been successfully used
previously to treat experimental brain tumor associated edema
[18].
Tissue Processing
For histological analysis animals were transcardially perfused at
2, 3 or 4 weeks following tumor cell inoculation (n= 6 per group).
Mice were terminally anaesthetised with an intraperitoneal
injection of pentobarbital (60 mg/kg) and perfused with 10%
formalin. Brains were removed, processed and embedded in
paraffin wax.
Immunohistochemistry
Assessment of immunohistochemistry was performed on six
sections containing tumor or corresponding level of control per
animal at 2, 3 and 4 weeks following tumor inoculation, and
representative images taken. Briefly, 5 mm coronal sections were
cut and stained with primary antibodies for SP (Santa Cruz;
1:2000), NK1 receptor (ATS; 1:8000) and Albumin (ICN
Pharmaceuticals, 1:20000). Following overnight incubation with
the primary antibodies, the appropriate secondary antibody was
applied (1:250), followed by streptavidin-peroxidase complex
(SPC, 1:1000) with bound antibody then detected with 3,39 –
diaminobenzidine (DAB) and sections counterstained with hae-
matoxylin.
Immunohistochemical Analysis
In combination with qualitative analysis, non-subjective estima-
tion of the level of albumin, SP and the NK1 receptor following
tumour cell inoculation was performed at the 3-week time point
using the colour deconvolution method [19]. Colour deconvolu-
tion determines the amount of DAB, and hence antigen within
each image to allow comparisons of positive staining between and
within animals. It is based on the mathematical method described
by Ruifrok and Johnston [20] for separation and quantification of
immunohistochemical staining by deconvolution of the colour
information in RGB images. This method reliably separates the
blue of haematoxylin from the brown of DAB within a section.
Previous experiments have demonstrated the reliability of this
method with a linear correlation demonstrated (extinction
coefficient 0.96) between increasing antibody concentration and
DAB weight [21].
Slides were stained using the DAB method and scanned at high
resolution using the Nanozoomer (Hamamatzu, Japan). Using the
associated software, images were taken of either the whole brain
(albumin, NK1 receptor) or the vessels within the peritumoural
region (SP). Jpeg images were then exported into ImageJ (v1.40 g
NIH, Bethesda, USA) and haematoxylin and DAB stains
separated using an NIH Image J macro, with background
subtraction and colour correction applied to the images [19].
NK1 Antagonist Treatment Reduces Peritumoral Edema
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Evans Blue
Permeability of the BBB was assessed using Evans blue (EB)
(Sigma, E-2129), a dye that tightly binds to albumin. Under
normal physiological circumstances, albumin is prevented from
entering the brain neuropil by the BBB. Thus, the amount of EB
dye within the brain tissue can be used to quantify BBB disruption.
At 4 weeks following tumor cell inoculation, animals were
placed under isoflurane anaesthesia and injected intravenously
with EB (2% EB, 2 mL/kg) 30 minutes prior to perfusion. Animals
were transcardially perfused with 0.9% saline until the perfusate
from the right atrium ran clear and subsequently decapitated and
brains rapidly removed. The olfactory bulbs and cerebellum were
discarded; the brain separated into left and right hemispheres and
placed in two Eppendorf containers.
Each sample was then weighed and homogenized in 3.75 mL of
PBS and 1.25 mL of 100% trichloroacetic acid solution (TCA)
(Sigma, T0699) and vortexed for 2 minutes. Samples were cooled
overnight at 4uC, and then centrifuged the following day for 30
minutes at 1000 g. The supernatants of each sample were
subsequently measured at 620 nm using a Synergy Mx plate
reader, with the amount of EB extravasation expressed as mg/g of
brain tissue using a previously obtained standard curve of EB
absorbance.
Edema Measurement
In order to assess brain water content, the wet weight dry weight
method was employed [11]. At 4 weeks following tumor cell
inoculation, animals were re-anaesthetised with pentobarbitone
and decapitated. Brains were rapidly removed from the skull, the
olfactory bulbs and cerebellum discarded and the remaining brain
separated into left and right hemispheres. Each hemisphere was
immediately weighed for wet brain weight. Following weighing,
tissue was immediately wrapped in pre-weighed, labelled alumin-
ium foil and placed in an oven for 72 hours at 100uC. Specimens
were then removed from the oven and re-weighed to obtain dry
brain water weight. Brain water content in each sample was then






All data are expressed as mean6SEM and were assessed using a
t-test or one or two-way ANOVA followed by Bonferonni post-
tests, as appropriate. A p value of less than 0.05 was deemed
significant in all experiments.
Results
Albumin is a large plasma protein that is normally prevented
from entering the brain tissue by the BBB. Thus, albumin
immunoreactivity was employed in this study to assess the integrity
of the BBB over the 4 weeks following tumor cell inoculation
(Figure 1). At 2 weeks following tumor inoculation a slight increase
in albumin staining was noted in the peritumoral area. With
continued tumor growth at 3 and 4 weeks post tumor inoculation,
a significant increase in albumin staining occurred such that the
disruption was no longer just in the immediate tumor vicinity but
had spread to the contralateral side.
A marked increase of perivascular SP staining compared to
controls was observed from 2 weeks following tumor cell
inoculation and persisted until the final time point of 4 weeks
(Figure 2). Due to the significant increase in BBB disruption as
observed with albumin quantification, the 3 week time point was
chosen for the quantification of SP and the NK1 receptor using
the color deconvolution method. This confirmed the qualitative
assessment, revealing a significant increase in perivascular SP
staining in tumor inoculated animals compared to controls at 3
weeks. Similarly, an obvious increase in NK1 receptor staining was
observed in the area surrounding the tumor such that it was
apparent using low power magnification (Figure 3). This was
particularly evident at the 3 weeks time point, and quantified using
color deconvolution. Indeed, a significant increase in overall NK1
receptor staining was evident at 3 weeks, as well as a significant
increase in NK1 receptor content in the tumor-inoculated
hemisphere when compared to the contralateral hemisphere of
the same animal. Only a moderate increase in perivascular NK1
receptor staining was evident at both 2 and 3 weeks following
tumor cell injection, however by 4 weeks a marked increase in
perivascular NK1 receptor immunoreactivity was observed
(Figure 3).
Given that marked BBB disruption evident at 3 weeks as
assessed by albumin staining, as well as corresponding significant
increases in SP and NK1 receptor immunoreactivity, this time
point was accordingly selected for intervention with the NK1
antagonist Emend. Following tumor cell inoculation, a significant
increase in both BBB permeability and brain water content
occurred compared to shams (Figure 4). Treatment with both the
NK1 antagonist Emend and dexamethasone resulted in a marked
reduction (p,0.05) in BBB permeability compared to vehicle-
Figure 1. Albumin as a marker of BBB dysfunction. In control
medium-injected animals, very little BBB disruption was evident at 2
weeks (A), 3 weeks (B) or 4 weeks (C) following injection. Conversely, in
tumor-inoculated animals an increase in albumin staining was evident
at 2 weeks (D) and extremely pronounced at 3 weeks (E) and 4 weeks
(F). This was confirmed using color deconvolution, which revealed a
highly significant increase in BBB disruption, as assessed by albumin
staining at both 3 and 4 weeks. Scale bars = 2 mm. Image are
representative of n= 6 per group. Color deconvolution analysis n = 6
per group/time point (** p,0.01, ***p,0.001 compared to controls).
doi:10.1371/journal.pone.0097002.g001
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treated animals such that both these treatment groups returned to
control levels by 1 week after treatment (Figure 4A). Evaluation of
brain water content showed a reduction with Emend treatment,
particularly within the right hemisphere. Indeed, NK1 antagonist
treatment reduced brain water content to a level that was no
longer significantly different compared to non-treated controls. In
contrast, brain water content within the right hemisphere in
vehicle (p,0.05) treated groups remained significantly increased
compared to control animals.
Discussion
Tumor-associated edema is one of the primary causes of CNS
symptoms in brain tumor patients, with clinical deficits more often
caused by edema than by the mass effect of the tumor itself. The
potential ability of NK1 antagonists to treat edema formation
associated with brain tumors is therefore of tremendous impor-
tance, especially given that the current standard treatment,
dexamethasone, is associated with a number of deleterious side
effects. The current study demonstrates that perivascular SP is
significantly increased in the peritumoral region, which is
consistent with previous studies demonstrating a role for SP in
the genesis of cerebral edema in models of acute brain injury
[10,11,22]. Administration of the NK1 antagonist Emend at 3
weeks post-inoculation resulted in a decrease in brain water
content and BBB permeability such that they were no longer
significantly different to sham animals within 7 days of treatment.
Additionally, the NK1 antagonist was effective as the current
standard treatment dexamethasone, at reducing BBB permeability
and edema formation.
Stereotaxic implantation of tumor cells into the brain is the most
commonly employed model of both primary and secondary brain
tumors. This model reliably produces tumors of similar size and
location, which allows for examination of many variables
associated with brain tumors. Furthermore, it has been commonly
used to detect tumor-induced changes in brain water content
[23,24]. In this study, a primary brain tumor cell line was not
employed as metastatic brain tumors are more common and are
associated with higher levels of edema formation [3,25–28].
Immunocompromised mice are routinely used in cancer research,
as the immune deficient nature of this strain allows for
examination of human cancer cells in an animal model [29].
However, one limitation of the use of these animals is the
translational potential of research carried out in immune deficient
species. Nonetheless, the results of the present study using
immunocompromised mice are consistent with previous studies
performed in immune competent animals, suggesting a dominant
role for SP and the NK1 receptor in neurogenic inflammation in a
variety of models of CNS disease [30–32]. Furthermore, the
pattern of SP immunoreactivity, as well as the observed decreases
in BBB permeability and brain water content are consistent among
these studies [10,12], highlighting the reproducibility of these
results in both immune-competent and deficient species, and thus
the translational potential of SP antagonists as a therapy for
cerebral edema.
In the present study, both SP and the NK1 receptor were
increased in the entire tumor-inoculated hemisphere when
compared to the contralateral side, indicating a possible role for
SP in mediating the process of edema formation within the
peritumoral region. Indeed, NK1 receptor staining was so
significantly increased in the peritumoral region such that it was
visible at low power. This correlated with the observed area of
albumin staining, implicating SP and in the genesis of BBB
breakdown and the development of cerebral edema. It was noted
that the increase in both albumin and NK1 receptor staining was
most pronounced at 3 weeks, and thus was chosen for
quantitation. However, this peak may be more a reflection of
model mortality given that a number of animals had to be
euthanased due to tumor burden before the 4-week time point.
Additionally, a marked increase in SP staining was observed in the
vasculature surrounding the tumor at all time points, further
supporting this proposed role.
The precise molecular mechanisms by which the NK1 receptor
and SP are upregulated in the setting of brain tumor edema have
yet to be fully elucidated. The link between inflammation and
cancer has been well established, with many chronic inflammatory
states associated with cancer development, as inflammation
increases both mitogenesis and mutagenesis [33] [15]. Similarly,
it is well known that both SP and the NK1 receptor are increased
in inflammatory conditions [34], with increased expression of SP
and NK1 receptor mRNA reported in response to inflammation
[35]. SP induces and augments many aspects of the inflammatory
response, including leukocyte activation, endothelial cell adhesion
molecule expression, cytokine production and mast cell activation
[36] [37]. SP may also prime polymorphonuclear cells for
oxidative metabolism, increasing the production of free radicals
[38]. NK1 receptors are expressed on astrocytes and are
implicated in the transformation to reactive astrocytes and
resultant production of inflammatory mediators [39]. Further-
more, it has been well documented that SP and the NK1 receptor
are upregulated in numerous cancer types, including melanoma
[14,15,40–43].
Administration of the NK1 antagonist Emend was found to
profoundly reduce BBB disruption and brain water content, such
Figure 2. SP immunolabelled sections of peritumoral vessels.
At 2 weeks (A), 3 weeks (B) and 4 weeks (C) following in culture medium
injected animals, minimal SP immunoreactivity was observed in the
vasculature. Following tumor cell inoculation at 2 weeks (D) a marked
increase in perivascular SP staining was evident, this intensity of
staining was sustained at both the 3 weeks (E) and 4 weeks (F) time
points. This was confirmed by color deconvolution analysis of
perivascular SP staining, which revealed a significant increase in SP
immunoreactivity in tumor inoculated animals when compared to
controls at 3 weeks (p = 0.039) (G). Images are representative of n = 6
per group. Scale bar = 50 mm. Color deconvolution analysis n = 6 per
group (*p,0.05 compared to controls).
doi:10.1371/journal.pone.0097002.g002
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that these groups were no longer significantly different to sham
animals. This is consistent with previous reports implicating SP in
the genesis of BBB disruption and edema formation following a
number of CNS pathologies. This edematous process is thought to
occur because SP induced NK1 receptor activation facilitates flux
of plasma proteins from the vascular lumen, either through gaps
opened between endothelial cells [44,45] or by increasing
transmembrane transport. Indeed, a recent study by Rodriguez
et al demonstrated that SP secreted by breast cancer cells mediates
their migration across the BBB. SP initiated changes in the
localisation and distribution of tight junction proteins ZO-1 and
Claudin-5, leading to increased permeability of the BBB, with SP
antagonism reducing tumor cell migration via modulation of the
BBB [46].
Additionally, the present study also found that treatment with
the NK1 antagonist was as effective at reducing levels of brain
edema as the current standard treatment, dexamethasone.
Interestingly, Glucocorticoids have previously been shown to
Figure 3. NK1 receptor immunoreactivity. A marked increase in NK1 receptor staining was observed in the area surrounding the tumor at 3
weeks (E) and 4 weeks (F) following tumor inoculation at low power when compared to the controls of the same time points (A–C). At 2 (G), 3 (H) and
4 (I) weeks following culture medium injection, there was minimal NK1 staining around the vasculature, especially when compared to the tumor
inoculated animals where a moderate increase was evident at 2 (J) and 3 (K) weeks, but clearly increased at 4 weeks (L). The qualitative assessment
was confirmed by color deconvolution, revealing a significant increase in overall NK1 receptor immunoreactivity when compared to controls
(p = 0.0327) (M) as well as a significant increase in NK1 receptor staining in the tumor inoculated hemisphere when compared to the contralateral
hemisphere of the same animals (p = 0.0086) (N). A–F Scale bars = 2 mm, G–L Scale bars = 50 mm. Images are representative of n = 6 per group. Color
deconvolution analysis n = 6 per group (*p,0.05 compared to controls).
doi:10.1371/journal.pone.0097002.g003
NK1 Antagonist Treatment Reduces Peritumoral Edema
PLOS ONE | www.plosone.org 5 May 2014 | Volume 9 | Issue 5 | e97002
increase the expression of NEP and ACE in cultured cells [47,48].
Both ACE and NEP catalyse the hydrolytic bonds of SP, cleaving
the peptide at its carboxyl terminal region required for SP to bind
to NK1 receptors and exert its effects [49]. Thus an increase in
NEP and ACE, may lead to a decrease in SP. However, no
significant changes in SP levels were observed following dexa-
methasone treatment in the present study, in vitro or in vivo (data
not shown). Further research is required to determine the effect of
dexamethasone on SP expression. Nonetheless, corticosteroids
have remained the treatment of choice for tumor-associated
edema for the past 40 years [50]. Stable patients with brain tumors
are usually started on corticosteroids at the time of diagnosis. They
are able to reduce cerebral edema in most patients by up to 70–
80% and facilitate symptomatic improvement [28]. Numerous
mechanisms of action have been described for corticosteroids,
however, in a broad sense, corticosteroids work by reducing the
permeability of a compromised BBB, thus effectively reducing
edema. However, dexamethasone is associated with a large
number of potentially serious side effects, the severity of which
depends on the dose and duration of steroid treatment [50].
Adverse side effects include immunosuppression, hypertension,
fluid retention and mood disturbances [51]. Emend is currently
clinically available as an anti-emetic for chemotherapy-induced
nausea, and is associated with minimal side effects.
We have previously demonstrated that Emend treatment may
reduce tumor growth by prohibiting further cellular proliferation
in this model of melanoma brain tumors [54]. Consequently, it is
plausible that the observed reduction in BBB disruption and
edema formation may be a reflection in the reduction in tumor
size. It has been previously reported that the BBB is intact in small
brain metastases, with angiogenesis and increased barrier perme-
ability only associated with tumors greater than 1 mm in size
[52,53]. Thus, smaller tumors are associated with less BBB
disruption and consequently less edema. Nonetheless, the results
observed in this study are consistent with the role of SP in the
genesis of edema in other neurological conditions, as well the SP
and NK1 receptor staining correlating with the areas of increased
BBB permeability. Thus, SP may potentially play multiple roles in
brain tumors, and given the side effects associated with
dexamethasone, warrants further investigation as a treatment for
tumor associated edema.
In conclusion, the present study has demonstrated that
treatment with the NK1 antagonist Emend significantly reduced
tumor-associated edema and BBB disruption in an in vivo model of
melanoma brain tumors. Furthermore, this treatment was as
effective as the treatment in current clinical use, dexamethasone,
thus supporting the development of therapeutics aimed at limiting
the effects of SP.
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